Back to results
US 2024/0180964 A1Published application
Chimeric cytokine receptors and uses thereof in cellular therapies
AssigneeNanjing Legend Biotech Co., Ltd.
InventorsQingling JIANG, Yafeng ZHANG, Yanliang ZHU, Miaomiao SHI, Shu WU
Life of this patent
Estimating the term…
Abstract
An immune effector cell expressing a chimeric cytokine receptor comprising a first extracellular antigen binding domain, a first transmembrane domain, and a cytokine receptor intracellular domain; and a functional exogenous receptor comprising a second extracellular antigen binding domain, a second transmembrane domain, and an intracellular signaling domain.
Claims78
An immune effector cell expressing
- (i) a chimeric cytokine receptor comprising:
- (a) a first extracellular antigen binding domain, wherein the first extracellular antigen binding domain is derived from NKG2D, truncated NKG2D, antibody or antigen binding fragment thereof targeting NKG2D ligands, TIGIT or SIRP-α, or a variant thereof,
- (b) a first transmembrane domain, and
- (c) a cytokine receptor intracellular domain;
- and
- (ii) optionally a functional exogenous receptor comprising:
- (a) a second extracellular antigen binding domain,
- (b) a second transmembrane domain, and
- (c) an intracellular signaling domain.
6 more elements
A polypeptide comprising:
- (i) a chimeric cytokine receptor comprising:
- (a) a first extracellular antigen binding domain, wherein the first extracellular antigen binding domain is derived from NKG2D, truncated NKG2D, antibody or antigen binding fragment thereof targeting NKG2D ligands, TIGIT or SIRP-α, or a variant thereof,
- (b) a first transmembrane domain, and
- (c) a cytokine receptor intracellular domain;
- and
- (ii) optionally a functional exogenous receptor comprising:
- (a) a second extracellular antigen binding domain,
- (b) a second transmembrane domain, and
- (c) an intracellular signaling domain.
6 more elements
An isolated nucleic acid comprising:
- (i) a first region encoding a chimeric cytokine receptor comprising:
- (a) a first extracellular antigen binding domain, wherein the first extracellular antigen binding domain is derived from NKG2D, truncated NKG2D, antibody or antigen binding fragment thereof targeting NKG2D ligands, TIGIT, or SIRP-α, or a variant thereof,
- (b) a first transmembrane domain, and
- (c) a cytokine receptor intracellular domain;
- and
- (ii) optionally a second region encoding a functional exogenous receptor comprising:
- (a) a second extracellular antigen binding domain,
- (b) a second transmembrane domain, and
- (c) an intracellular signaling domain.
6 more elements
Dependencies are inferred from the claim text.